NewsBenzingaBarclays Maintains Overweight on Insmed, Lowers Price Target to $207 Barclays Maintains Overweight on Insmed, Lowers Price Target to $207 Benzinga 2026.09.30 15:37 (GMT+0) Open on Benzinga Other news Chainflip Halts Swaps Over Potential Vault Exploit Nvidia Plunges 14% in a Single Day; Dan Bin Responds to "Liquidation Line": Some Funds Can Only Cut Positions Passively Analysis: This Is Not an AI Bubble Bursting but a Normal Pullback; Even a Further 10% Drop in the S&P 500 Would Still Be a Healthy Correction Chainflip Hacked, Losing About $4.86 Million Sabre Corporation (SABR) Analyst/Investor Day - Slideshow Sabre Corporation (SABR) Analyst/Investor Day Transcript
Nvidia Plunges 14% in a Single Day; Dan Bin Responds to "Liquidation Line": Some Funds Can Only Cut Positions Passively
Analysis: This Is Not an AI Bubble Bursting but a Normal Pullback; Even a Further 10% Drop in the S&P 500 Would Still Be a Healthy Correction